EP2759533B1 - Kondensierte heterocyclische verbindung - Google Patents

Kondensierte heterocyclische verbindung Download PDF

Info

Publication number
EP2759533B1
EP2759533B1 EP12833546.0A EP12833546A EP2759533B1 EP 2759533 B1 EP2759533 B1 EP 2759533B1 EP 12833546 A EP12833546 A EP 12833546A EP 2759533 B1 EP2759533 B1 EP 2759533B1
Authority
EP
European Patent Office
Prior art keywords
group
compound
optionally substituted
formula
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP12833546.0A
Other languages
English (en)
French (fr)
Other versions
EP2759533A1 (de
EP2759533A4 (de
Inventor
Satoshi Yamamoto
Junya Shirai
Yoshiyuki Fukase
Yoshihide Tomata
Ayumu Sato
Atsuko OCHIDA
Kazuko Yonemori
Hideyuki Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP2759533A1 publication Critical patent/EP2759533A1/de
Publication of EP2759533A4 publication Critical patent/EP2759533A4/de
Application granted granted Critical
Publication of EP2759533B1 publication Critical patent/EP2759533B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Definitions

  • the present invention relates to a fused heterocyclic compound having an ROR ⁇ t inhibitory action, and a medicament containing the compound.
  • Th17 cell and inflammatory cytokine produced thereby cause various autoimmune disease such as inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis or psoriasis, and a decrease in QOL as a severe etiology cell and factor accompanying enhancement of a systemic new immune response.
  • IBD inflammatory bowel disease
  • rheumatoid arthritis multiple sclerosis or psoriasis
  • QOL a severe etiology cell and factor accompanying enhancement of a systemic new immune response.
  • the existing therapeutic drugs show only limited effects, and therefore, the earliest possible development of a novel therapeutic drug has been desired.
  • T cells inter alia, Th17 cell and inflammatory cytokines (IL-17A, IL-17F and the like) produced thereby, in the pathology of these autoimmune disease has been drawing attention in recent years.
  • ROR ⁇ t Retinoid-related Orphan Receptor ⁇ t, which is one of the orphan nuclear receptors, plays an important role in the differentiation of Th17 cells and production of IL-17A/IL-17F. That is, it has been reported that ROR ⁇ t is mainly expressed in Th17 cells and functions as a transcription factor of IL-17A and IL-17F, as well as a master regulator of Th17 cell differentiation (non-patent documents 1 and 2).
  • a medicament that inhibits the action of ROR ⁇ t is expected to show a treatment effect on various autoimmune disease by suppressing differentiation and activation of Th17 cells.
  • patent document 1 describes a compound represented by the formula: wherein r5 and r6 may together form
  • non-patent document 3 describes a compound represented by the formula: (SR1001) and non-patent document 4 describes a compound represented by the formula: (TO901317).
  • non-patent document 5 describes a compound represented by the formula: (Digoxin).
  • non-patent document 6 describes a compound represented by the formula: (SR1078).
  • non-patent document 7 describes a compound represented by the formula: (Ursolic acid).
  • non-patent document 8 describes compounds represented by the formulas: (7 ⁇ -hydroxycholesterol) (7 ⁇ -hydroxycholesterol) (24-ketocholesterol), and non-patent document 9 describes a compound represented by the formula: (24S-hydroxycholesterol).
  • non-patent document 10 describes compounds represented by the formulas:
  • patent document 1 WO 2010/049144
  • the present invention aims to provide a compound having a superior ROR ⁇ t inhibitory action, and is useful as an agent for the prophylaxis or treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, and/or psoriasis.
  • IBD inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn's disease
  • rheumatoid arthritis multiple sclerosis
  • psoriasis psoriasis
  • the present inventors have found that a compound represented by the following formula (I') or a salt thereof has a superior ROR ⁇ t inhibitory action based on the specific chemical structure thereof and affords superior efficacy as an agent for the prophylaxis or treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, and/or psoriasis.
  • IBD inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn's disease
  • rheumatoid arthritis multiple sclerosis
  • psoriasis psoriasis
  • present invention relates to
  • the compound of the present invention has a superior ROR ⁇ t inhibitory action, and is useful as an agent for the prophylaxis or treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, and/or psoriasis.
  • IBD inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn's disease
  • rheumatoid arthritis multiple sclerosis
  • psoriasis psoriasis
  • examples of the "optionally substituted hydrocarbon group” include an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aralkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group, and an optionally substituted cycloalkenyl group.
  • examples of the "optionally substituted alkyl group” include a C 1-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neo-pentyl, hexyl etc.) optionally having substituent(s) selected from
  • examples of the "optionally substituted alkenyl group” include a C 2-6 alkenyl group (e.g., vinyl, 1-propenyl, allyl, isopropenyl, butenyl, isobutenyl etc.) optionally having 1 to 4, preferably 1 to 3, substituents which the alkyl group of the above-defined "optionally substituted alkyl group” optionally has.
  • the number of the substituents is 2 or more, the respective substituents may be the same or different.
  • examples of the "optionally substituted alkynyl group” include a C 2-6 alkynyl group (e.g., ethynyl, propargyl, butynyl, 1-hexynyl etc.) optionally having 1 to 4, preferably 1 to 3, substituents which the alkyl group of the above-defined "optionally substituted alkyl group” optionally has.
  • the number of the substituents is 2 or more, the respective substituents may be the same or different.
  • examples of the "optionally substituted aralkyl group” include a C 7-12 aralkyl group (e.g., benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl and the like) optionally having 1 to 4, preferably 1 to 3,
  • examples of the "optionally substituted aryl group” include a C 6-14 aryl group (e.g., phenyl, naphthyl) optionally having 1 to 4, preferably 1 to 3, substituents which the aralkyl group of the above-defined "optionally substituted aralkyl group” optionally has.
  • the respective substituents may be the same or different.
  • examples of the "optionally substituted cycloalkyl group” include a C 3-8 cycloalkyl group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) optionally having 1 to 4, preferably 1 to 3, substituents which the aralkyl group of the above-defined "optionally substituted aralkyl group” optionally has.
  • the number of the substituents is 2 or more, the respective substituents may be the same or different.
  • substituents for "optionally substituted cycloalkyl group” are optionally bonded to form a ring (a cycloalkane ring (a C 3-6 cycloalkane ring such as a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring), an arene ring (a C 6-10 arene ring such as a benzene ring, a naphthalene ring)).
  • a cycloalkane ring a C 3-6 cycloalkane ring such as a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring
  • an arene ring a C 6-10 arene ring such as a benzene ring, a naphthalene ring
  • examples of the "optionally substituted cycloalkenyl group” include C 3-8 cycloalkenyl group (e.g., cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl) optionally having 1 to 4, preferably 1 to 3, substituents which the aralkyl group of the above-defined "optionally substituted aralkyl group” optionally has.
  • the respective substituents may be the same or different.
  • substituents for the "optionally substituted cycloalkenyl group” are optionally bonded to form a ring (a cycloalkane ring (a C 3-6 cycloalkane ring such as a cyclopropane ring, a cyclobutane ring, a cyclopentane ring and a cyclohexane ring), an arene ring (a C 6-10 arene ring such as a benzene ring and a naphthalene ring)).
  • a cycloalkane ring a C 3-6 cycloalkane ring such as a cyclopropane ring, a cyclobutane ring, a cyclopentane ring and a cyclohexane ring
  • an arene ring a C 6-10 arene ring such as a benzene ring and a naphthalene ring
  • halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • R 1A is a C 1-6 alkyl group (e.g., methyl, ethyl, propyl, isobutyl), preferably methyl, ethyl, propyl or isobutyl.
  • R 2A and R 3A are preferably each independently a hydrogen atom or a C 1-6 alkyl group (e.g., methyl), particularly preferably a hydrogen atom or methyl.
  • R 2A and R 3A form, together with the carbon atoms which they are bonded to, an arene ring (e.g., a benzene ring) or a cycloalkene ring (e.g., a cyclohexene ring), preferably a benzene ring or a cyclohexene ring.
  • an arene ring e.g., a benzene ring
  • a cycloalkene ring e.g., a cyclohexene ring
  • R 5A is a hydrogen atom or a halogen atom.
  • R 5A is preferably a hydrogen atom or a chlorine atom, more preferably a hydrogen atom.
  • Q' is a bivalent group selected from
  • Ring B' is a benzene ring optionally having additional substituent(s), or a pyridine ring optionally having additional substituent(s).
  • the "substituent" of the "benzene ring optionally having additional substituent(s)" for Ring B' is selected from a halogen atom (e.g., a chlorine atom), a cyano group, a C 1-6 alkoxy group (e.g., methoxy), and a C 1-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), preferably selected from a chlorine atom, cyano, methoxy, methyl and trifluoromethyl.
  • the "benzene ring optionally having additional substituent (s) preferably has no substituent(s).
  • the "substituent" of the "pyridine ring optionally having additional substituent(s)" for Ring B' is a C 1-6 alkyl group (e.g., methyl), preferably methyl. In another embodiment, the "pyridine ring optionally having additional substituent(s)” preferably has no substituent(s).
  • Compound (I') is a compound wherein R 1A is a C 1-6 alkyl group (e.g., methyl, ethyl, propyl, isobutyl); R 2A and R 3A are each independently a hydrogen atom or a C 1-6 alkyl group (e.g., methyl), or R 2A and R 3A form, together with the carbon atoms which they are bonded to, an arene ring (e.g., a benzene ring) or a cycloalkene ring (e.g., a cyclohexene ring); Q' is a bivalent group selected from
  • Compound (I') is preferably a compound wherein R 1A is methyl, ethyl, propyl or isobutyl; R 2A and R 3A are each a hydrogen atom or methyl, or R 2A and R 3A form, together with the carbon atoms which they are bonded to, a benzene ring or a cyclohexene ring; Q' is a bivalent group selected from
  • Examples of the above-mentioned compound (I') include the compounds of Examples. Among them, N-(4-cyanophenyl)-N'-(9-ethyl-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-3-methylpentanediamide or a salt thereof (Example 4), N-(3-chloro-4-cyanophenyl)-N'-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide or a salt thereof (Example 14), and N- ⁇ 4-[(3-chloro-4-cyanophenyl)amino]-2-methyl-4-oxobutyl ⁇ -9-ethyl-9H-carbazole-3-carboxamide or a salt thereof (Example 48) are preferable.
  • salts of compound (I') include metal salts, ammonium salts, salts with organic base, salts with inorganic acid, salts with organic acid, salts with basic or acidic amino acids.
  • metal salt include alkaline metal salts such as sodium salt, potassium salt; alkaline earth metal salts such as calcium salt, magnesium salt, barium salt; aluminum salts.
  • salt with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine.
  • Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid.
  • Preferable examples of the salt with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid.
  • Preferable examples of the salt with basic amino acid include salts with arginine, lysine, ornithine.
  • Preferable examples of the salt with acidic amino acid include salt with aspartic acid, glutamic acid.
  • salts are preferable.
  • examples of the salt include inorganic salts such as alkaline metal salts (e.g., sodium salt, potassium salt), alkaline earth metal salts (e.g., calcium salt, magnesium salt, barium salt); ammonium salt.
  • examples of the salt thereof include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and salts with organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid
  • organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid.
  • the intermediates produced in the following production methods may be isolated and purified according to methods such as column chromatography, recrystallization, distillation and the like, or may be directly used without isolation for the next step.
  • the compound (I'a)-compound (I'p) [i.e., compound (I'), wherein Q' in the formula (I') is each the bivalent group (I'a)-(I'p)] or a salt thereof of the present invention can be produced according to following Method A to Method L.
  • R 6 is an optionally substituted hydrocarbon group
  • L is a leaving group
  • the other each symbols are as defined above.
  • Examples of the leaving group for L include halogen atoms (a chlorine atom, a bromine atom, an iodine atom etc.), substituted sulfonyloxy groups (C 1-6 alkylsulfonyloxy groups such as methanesulfonyloxy, ethanesulfonyloxy and the like; C 6-14 arylsulfonyloxy groups such as benzenesulfonyloxy, p-toluenesulfonyloxy and the like; C 7-16 aralkylsulfonyloxy groups such as benzylsulfonyloxy and the like, etc.), acyloxy groups (acetoxy, benzoyloxy etc.), oxy groups substituted by heterocycle or aryl group (succinimide, benzotriazole, quinoline, 4-nitrophenyl etc.), heterocycle (imidazole etc.) and the like.
  • halogen atoms
  • This step is a step of producing compound (IV) or a salt thereof by reacting compound (IIa) or a salt thereof with compound (III) or a salt thereof.
  • Compound (IIa) and compound (III) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • compound (IV) or a salt thereof is produced by reacting compound (IIa) or a salt thereof with compound (III) or a salt thereof
  • the reaction can be performed in a solvent that does not adversely influence the reaction.
  • the solvent include alcohols (methanol, ethanol, propanol, 2-propanol, butanol, isobutanol, t-butanol etc.), hydrocarbons (benzene, toluene etc.), ethers (diethyl ether, dioxane, tetrahydrofuran etc.), esters (ethyl acetate etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), amides (N,N-dimethylformamide etc.) and the like, and they may be mixed as appropriate.
  • tetrahydrofuran is preferably used.
  • the amount of compound (III) to be used is generally about 0.5 to 10 mol equivalent, preferably about 0.9 to 1.1 mol equivalent, per 1 mol of compound (IIa).
  • the reaction temperature is generally about -80 to 200°C, preferably about 25 to 150°C, and the reaction time is generally about 0.5 to 72 hr, preferably 1 to 48 hr.
  • This step is a step of producing compound (I'a) or a salt thereof by reacting compound (IV) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • Compound (V) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • condensing agent used in this step examples include dicyclohexylcarbodiimide, diisopropylcarbodiimide, N-ethyl-N'-3-dimethylaminopropylcarbodiimide and a hydrochloride thereof, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphorate, diphenylphosphorylazide and the like. They can be used alone or in combination with an additive (e.g., N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine etc.).
  • an additive e.g., N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine etc.
  • the amount of the condensing agent to be used is about 1 to 10 mol equivalent, preferably about 1 to 2 mol equivalent, per 1 mol of compound (IV).
  • the amount of the additive to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 2 mol equivalent, per 1 mol of compound (IV).
  • the amount of compound (V) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 2 mol equivalent, per 1 mol of compound (IV).
  • the above-mentioned reaction is generally performed in a solvent that does not adversely influence the reaction, and a base may be added for the progress of the reaction.
  • a solvent include hydrocarbons (benzene, toluene etc.), ethers (diethyl ether, dioxane, tetrahydrofuran etc.), esters (ethyl acetate etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), amides (N,N-dimethylformamide etc.) and the like, and they may be mixed as appropriate.
  • Examples of the base include alkali metal hydroxides (sodium hydroxide, potassium hydroxide etc.), hydrogen carbonates (sodium hydrogen carbonate, potassium hydrogen carbonate etc.), carbonates (sodium carbonate, potassium carbonate etc.), acetates (sodium acetate etc.), tertiary amines (trimethylamine, triethylamine, N-methylmorpholine etc.), aromatic amines (pyridine, picoline, N,N-dimethylaniline etc.) and the like.
  • the amount of the base to be used is generally about 1 to 100 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of the substrate.
  • the reaction temperature is generally about -80 to 150°C, preferably about 0 to 50°C
  • the reaction time is generally about 0.5 to 100 hr, preferably 0.5 to 60 hr.
  • This step is a step of producing compound (I'b') or a salt thereof by reacting compound (I'a) or a salt thereof with compound (VIIa) or a salt thereof in the presence of a base.
  • Compound (VIIa) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the base used in this step include inorganic bases (alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, alkali metal hydrogen carbonates such as sodium hydrogen carbonate, potassium hydrogen carbonate and the like, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate and the like, alkali metal alkoxides such as sodium methoxide, sodium ethoxide and the like, and the like), organic bases (amines such as trimethylamine, triethylamine, diisopropylethylamine and the like, cyclic amines such as pyridine, 4-dimethylaminopyridine and the like, and the like) and the like.
  • inorganic bases alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydroxide, sodium hydrox
  • sodium hydride is preferable. While the amount of the base to be used varies depending on the kind of the solvent and the other reaction conditions, it is generally about 1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of compound (I'a).
  • the amount of compound (VIIa) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (I'a).
  • This step is performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like. Among these, N,N-dimethylformamide is preferable.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 25 to 100°C. While the reaction time varies depending on the kind of compound (I'a) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (VI) or a salt thereof by subjecting compound (IV) or a salt thereof to esterification.
  • This reaction is a step of producing compound (VI) or a salt thereof by subjecting compound (IV) or a salt thereof to a dehydration reaction with the compound represented by the formula R 6 -OH (XXXVI) wherein each symbol is as defined above (hereinafter sometimes to be referred to as compound (XXXVI)) or a salt thereof in the presence of an acid catalyst, or to an alkylation reaction with the compound represented by the formula R 6 -L (XXXVII) wherein each symbol is as defined above (hereinafter sometimes to be referred to as compound (XXXVII)) in the presence of a base.
  • Compound (XXXVI) and compound (XXXVII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the acid catalyst used for the reaction of compound (IV) or a salt thereof with compound (XXXVI) or a salt thereof include mineral acids (hydrochloric acid, sulfuric acid etc.), organic sulfonic acids (methanesulfonic acid, p-toluenesulfonic acid etc.), Lewis acids (boron fluoride etherate etc.) and the like. While the amount of the acid catalyst to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 0.0001 to 10 mol equivalent, preferably about 0.01 to 0.1 mol equivalent, per 1 mol of compound (IV).
  • the amount of compound (XXXVI) to be used is generally about 1 to 1000 mol equivalent, preferably about 10 to 100 mol equivalent, per 1 mol of compound (IV).
  • solvent used for the reaction examples include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.) and the like.
  • Compound (XXXVI) may be used as a solvent.
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 25 to 100°C. While the reaction time varies depending on the kind of compound (IV) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • Examples of the base used for the reaction of compound (IV) or a salt thereof with compound (XXXVII) or a salt thereof include inorganic bases (alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, alkali metal hydrogen carbonates such as sodium hydrogen carbonate, potassium hydrogen carbonate and the like, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate and the like, etc.). While the amount of the base to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of compound (IV).
  • the amount of compound (XXXVII) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (IV).
  • This step is performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 25 to 100°C. While the reaction time varies depending on the kind of compound (IV) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (VIII) or a salt thereof by reacting compound (VI) or a salt thereof with compound (VIIb) or a salt thereof in the presence of a base.
  • This step can be performed in the same manner as in the method described in Step 3 of Method A.
  • Compound (VIIb) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of converting compound (VIII) or a salt thereof to compound (IX) or a salt thereof by hydrolysis.
  • This reaction can be performed according to a method known per se, generally in the presence of an acid or a base, where necessary, in a solvent that does not adversely influence the reaction.
  • the acid examples include mineral acids (hydrochloric acid, hydrobromic acid, sulfuric acid etc.), carboxylic acids (acetic acid, trifluoroacetic acid, trichloroacetic acid etc.), sulfonic acids (methanesulfonic acid, toluenesulfonic acid etc.), Lewis acids (aluminium chloride, tin chloride, zinc bromide etc.) and the like. Where necessary, they may be used in a mixture of two or more kinds thereof. While the amount of the acid to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 0.1 mol equivalent or more per 1 mol of compound (VIII). The acid may be used as a solvent.
  • the base examples include inorganic bases (alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, alkali metal hydrogen carbonates such as sodium hydrogen carbonate, potassium hydrogen carbonate and the like, alkali metal carbonates such as sodium carbonate, potassium carbonate and the like, alkoxides such as sodium methoxide, sodium ethoxide and the like, etc.), organic bases (amines such as trimethylamine, triethylamine, diisopropylethylamine and the like, cyclic amines such as pyridine, 4-dimethylaminopyridine and the like, etc.) and the like.
  • sodium hydroxide is preferable. While the amount of the base to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 0.1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of compound (VIII).
  • Examples of the solvent that does not adversely influence the reaction include alcohols (methanol, ethanol, propanol, 2-propanol, butanol, isobutanol, t-butanol etc.), hydrocarbons (benzene, toluene, xylene, hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), carboxylic acids (acetic acid etc.), amides (N,N-dimethylformamide, dimethylacetamide etc.), sulfoxides (dimethylsulfoxide etc.), water and the like. Among these, ethanol, tetrahydrofuran and water are preferable.
  • the reaction temperature is, for example, within about - 50 to 200°C, preferably about 0 to 100°C. While the reaction time varies depending on the kind of compound (VIII) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (I'c) or a salt thereof by reacting compound (IX) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (I'b) or a salt thereof by reacting compound (I'c) or a salt thereof with compound (VIIa) or a salt thereof in the presence of a base.
  • This step can be performed in the same manner as in the method described in Step 3 of Method A.
  • This step is a step of producing compound (X) or a salt thereof by treating compound (IV) or a salt thereof with a reducing agent.
  • Examples of the reducing agent used in this step include metal hydrides (sodium borohydride, lithium borohydride, zinc borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, lithium cyanoborohydride, dibutylaluminium hydride, aluminium hydride, lithium aluminium hydride etc.), borane complexs (borane-tetrahydrofuran complex, catecholborane etc.) and the like. Among these, borane-tetrahydrofuran complex is preferable.
  • the amount of the reducing agent to be used is, for example, about 1 to 50 mol equivalent, preferably about 1 to 10 mol equivalent, per 1 mol of compound (IV).
  • reaction solvent examples include aromatic hydrocarbons (toluene, xylene etc.), aliphatic hydrocarbons (heptane, hexane etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), alcohols (methanol, ethanol, 2-propanol, butanol, benzyl alcohol etc.), nitriles (acetonitrile etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • aromatic hydrocarbons toluene, xylene etc.
  • aliphatic hydrocarbons heptane, hexane etc.
  • halogenated hydrocarbons chloroform, dichloromethane etc.
  • ethers diethyl ether, tetrahydrofuran, diox
  • the reaction temperature is generally about -80°C to 100°C, preferably about 0°C to 40°C, and the reaction time is generally 5 min to 48 hr, preferably 1 to 24 hr.
  • This step is a step of producing compound (XI) or a salt thereof by treating compound (X) or a salt thereof with an oxidizing agent.
  • oxidizing agent used in this step examples include chromic acids (pyridinium chlorochromate (PCC), pyridinium dichromate (PDC) etc.), active manganese dioxides, dimethylsulfoxide-electrophiles (examples of the electrophile include oxalyl chloride, dicyclohexylcarbodiimide (DCC), acetic anhydride, trifluoroacetic anhydride, thionyl chloride, chlorine, N-chlorosuccinimide (NCS) etc.), oxoammonium salts (4-(benzoyloxy)-2,2,6,6-tetramethylpiperidin-l-oxyl etc.), tetrapropylammonium perruthenates (TPAP)-4-methylmorpholine N-oxide, hypervalent iodines (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Desss
  • reaction solvent examples include aromatic hydrocarbons (toluene, xylene etc.), aliphatic hydrocarbons (heptane, hexane etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), alcohols (methanol, ethanol, 2-propanol, butanol, benzyl alcohol etc.), nitriles (acetonitrile etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like. These solvent may be used in a mixture thereof in an appropriate ratio.
  • reaction temperature varies depending on the kind of the oxidizing agent, it is generally about -78°C to about 200°C, preferably about 0°C to about 100°C, and the reaction time is generally about 0.5 hr to about 48 hr, preferably about 0.5 hr to about 24 hr.
  • This step is a step of producing compound (I'd) or a salt thereof by subjecting compound (XI) or a salt thereof to a reductive alkylation reaction with compound (V) or a salt thereof.
  • the reductive alkylation reaction in this step can be performed according to a method known per se, for example, by reacting compound (XI) or a salt thereof with compound (V) or a salt thereof, and subjecting the resulting imine or iminium ion to a reduction reaction.
  • the amount of compound (V) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (XI).
  • the solvent used for the reaction for producing imine or iminium ion is not particularly limited as long as the reaction proceeds.
  • examples thereof include hydrocarbons (heptane, hexane, toluene, xylene etc.), halogenated hydrocarbons (chloroform, dichloromethane, 1,2-dichloroethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), esters (ethyl acetate, t-butyl acetate etc.), alcohols (methanol, ethanol, 2-propanol etc.), nitriles (acetonitrile, butyronitrile etc.), amides (N,N-dimethylformamide, dimethylacetamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like, and mixed solvents thereof.
  • the reaction can advantageously proceeds by the addition of a catalyst.
  • the catalyst include mineral acids (hydrochloric acid, hydrobromic acid, sulfuric acid etc.), carboxylic acids (formic acid, acetic acid, propionic acid, trifluoroacetic acid etc.), sulfonic acids (methanesulfonic acid, p-toluenesulfonic acid etc.), Lewis acids (aluminium chloride, zinc chloride, zinc bromide, boron trifluoride, titanium chloride etc.), acetates (sodium acetate, potassium acetate etc.), molecular sieves (molecular sieve 3A, 4A, 5A etc.), dehydrating agents (magnesium sulfate etc.) and the like.
  • the amount of the catalyst to be used is generally 0.01 to 50 mol equivalent, preferably about 0.1 to about 10 mol, per 1 mol of compound (XI).
  • the reaction temperature is generally about 0°C to about 200°C, preferably about 20°C to about 150°C, and the reaction time is generally about 0.5 hr to about 48 hr, preferably about 0.5 hr to about 24 hr.
  • the conversion of the imine or iminium ion to compound (I'd) can be performed according to various reduction reaction in a solvent inert to the reaction.
  • the reduction reaction can be performed according to a method known per se, and examples thereof include a method using a metal hydride, and method employing hydrogenation reaction.
  • the metal hydride examples include sodium borohydride, lithium borohydride, zinc borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, lithium cyanoborohydride, dibutylaluminium hydride, aluminium hydride, lithium aluminium hydride, borane complexs (borane-THF complex, catecholborane etc.) and the like, and sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride and the like are preferable.
  • the amount of the metal hydride to be used is, for example, about 1 to about 50 mol, preferably about 1 to about 10 mol, per 1 mol of the imine.
  • the reduction reaction using a metal hydride is performed generally in a solvent inert to the reaction.
  • the solvent include aromatic hydrocarbons (toluene, xylene etc.), aliphatic hydrocarbons (heptane, hexane etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), alcohols (methanol, ethanol, 2-propanol, butanol, benzyl alcohol etc.), nitriles (acetonitrile etc.), N,N-dimethylformamide, dimethylsulfoxide and the like. These solvent may be used in a mixture thereof in an appropriate ratio.
  • the reaction temperature is generally about -80°C to about 80°C, preferably about -40°C to about 40°C, and the reaction time is generally about 5 min to about 48 hr, preferably about 1 hr to about 24 hr.
  • the catalytic hydrogenation reaction can be performed in the presence of a catalyst under hydrogen atmosphere.
  • the catalyst include palladiums such as palladium on carbon, palladium hydroxide on carbon, palladium oxide and the like; nickels such as Raney-nickel catalyst and the like; platinums such as platinum oxide, platinum on carbon and the like; rhodiums such as rhodium on carbon and the like, and the like.
  • the amount thereof to be used is generally about 0.001 to about 1 mol, preferably about 0.01 to about 0.5 mol, per 1 mol of the imine or oxime.
  • the catalytic hydrogenation reaction is performed generally in a solvent inert to the reaction.
  • the solvent include alcohols (methanol, ethanol, propanol, butanol etc.), hydrocarbons (benzene, toluene, xylene etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, dioxane, tetrahydrofuran etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), carboxylic acids (acetic acid etc.), water and mixtures thereof.
  • the hydrogen pressure for the reaction is generally about 1 to about 50 atm, preferably about 1 to about 10 atm.
  • the reaction temperature is generally about 0°C to about 150°C, preferably about 20°C to about 100°C, and the reaction time is generally about 5 min to about 72 hr, preferably about 0.5 hr to about 40 hr.
  • compound (I'd) can also be obtained directly from compound (XI).
  • the pH of the reaction mixture is preferably adjusted to about 4 to about 5.
  • This step is a step of producing compound (XIII) or a salt thereof by reacting compound (XII) or a salt thereof with compound (V) or a salt thereof.
  • This step can be performed in the same manner as in the method described in Step 1 of Method A.
  • Compound (XII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (I'e) or a salt thereof by reacting compound (XIII) or a salt thereof with compound (XIV) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XIV) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XVI) or a salt thereof by reacting compound (XV) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XV) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XVII) or a salt thereof by subjecting compound (XVI) or a salt thereof to a deprotection reaction.
  • the deprotection reaction can be performed according to a known method (e.g., Wiley-Interscience, 1999, "Protective Groups in Organic Synthesis, 3rd Ed.” (Theodora W. Greene, Peter G. m. Wuts )).
  • a known method e.g., Wiley-Interscience, 1999, "Protective Groups in Organic Synthesis, 3rd Ed.” (Theodora W. Greene, Peter G. m. Wuts )
  • the reaction is performed depending on the kind of compound (XVI), it is generally performed in the presence of an acid, where necessary, in a solvent that does not adversely influence the reaction.
  • the acid examples include mineral acids (hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride etc.), carboxylic acids (acetic acid, trifluoroacetic acid, trichloroacetic acid etc.), sulfonic acids (methanesulfonic acid, p-toluenesulfonic acid etc.), Lewis acids (aluminium chloride, tin chloride, zinc bromide etc.) and the like.
  • the acid may be used in a mixture of two or more kinds thereof. While the amount of the acid to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 0.1 mol equivalent or more per 1 mol of compound (XVI).
  • the acid may be used as a solvent.
  • Examples of the solvent that does not adversely influence the reaction include alcohols (methanol, ethanol, propanol, 2-propanol, butanol, isobutanol, t-butanol etc.), aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), carboxylic acids (acetic acid etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.), water and the like, and mixed solvents
  • the reaction temperature is, for example, within about - 50 to 200°C, preferably about 0 to 100°C. While the reaction time varies depending on the kind of compound (XVI), the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (I'f) or a salt thereof by reacting compound (XVII) or a salt thereof with compound (XVIII) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XVIII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XX) or a salt thereof by reacting compound (XIX) or a salt thereof with compound (XIV) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XIX) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XXI) or a salt thereof by subjecting compound (XX) or a salt thereof to a deprotection reaction.
  • This step can be performed in the same manner as in the method described in Step 2 of Method D.
  • This step is a step of producing compound (I'g) or a salt thereof by reacting compound (XXI) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (XXIII) or a salt thereof by reacting compound (XXII) or a salt thereof with compound (XVIII) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XXII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XXIV) or a salt thereof by subjecting compound (XXIII) or a salt thereof to a deprotection reaction.
  • This step can be performed in the same manner as in the method described in Step 2 of Method D.
  • This step is a step of producing compound (I'h) or a salt thereof by reacting compound (XXIV) or a salt thereof with compound (XXXIX) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (XXVI) or a salt thereof by reacting compound (XXII) or a salt thereof with compound (XXV) or a salt thereof in the presence of a base.
  • Compound (XXV) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the base used for this reaction include inorganic bases (alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, alkali metal hydrogen carbonates such as sodium hydrogen carbonate, potassium hydrogen carbonate and the like, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate and the like, alkali metal alkoxides such as sodium methoxide, sodium ethoxide and the like, etc.), organic bases (amines such as trimethylamine, triethylamine, diisopropylethylamine and the like, cyclic amines such as pyridine, 4-dimethylaminopyridine and the like, etc.) and the like. While the amount of the base to be used varies depending on the kind of the solvent and other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1
  • the amount of compound (XXV) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (XXII).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • tetrahydrofuran, acetonitrile and N,N-dimethylformamide are preferable.
  • These solvent may be used in
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 50 to 100°C. While the reaction time varies depending on the kind of compound (XXII) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (XXVII) or a salt thereof by subjecting compound (XXVI) or a salt thereof to a deprotection reaction.
  • This step can be performed in the same manner as in the method described in Step 2 of Method D.
  • This step is a step of producing compound (I'i) or a salt thereof by reacting compound (XXVII) or a salt thereof with compound (XXXIX) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (XXIX) or a salt thereof by reacting compound (XXVIII) or a salt thereof with compound (V) or a salt thereof in the presence of an additive.
  • Compound (XXVIII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the additive used for this reaction include aluminium reagents (trimethylaluminum, aluminium chloride etc.), tin reagents (tetramethyltin etc.), Grignard reagents (methylmagnesium chloride, methylmagnesium bromide, methylmagnesium iodide, ethylmagnesium chloride, ethylmagnesium bromide, ethylmagnesium iodide etc.), bases (butyllithium, sodium hydride, sodium methoxide etc.) and the like. While the amount of the additive to be used varies depending on the kind of the solvent and the other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of compound (V).
  • the amount of compound (V) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (XXVIII).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 50 to 100°C. While the reaction time varies depending on the kind of compound (XXVIII) or a salt thereof, the kind of compound (V) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (I'j) or a salt thereof by reacting compound (XXIX) or a salt thereof with compound (XXX) or a salt thereof in the presence of a base.
  • Compound (XXX) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the base used for this reaction include inorganic bases (alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, alkali metal hydrogen carbonates such as sodium hydrogen carbonate, potassium hydrogen carbonate and the like, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate and the like, alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium-t-butoxide and the like, etc.), organic bases (amines such as trimethylamine, triethylamine, diisopropylethylamine and the like, cyclic amines such as pyridine, 4-dimethylaminopyridine and the like etc.) and the like.
  • inorganic bases alkali metal hydrides such as sodium hydride, lithium hydride and the like, alkali metal hydroxides such as lithium hydrox
  • sodium hydride and potassium-t-butoxide are preferable. While the amount of the base to be used varies depending on the kind of the solvent and other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 5 mol equivalent, per 1 mol of compound (XXIX).
  • the amount of compound (XXX) to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (XXIX).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • tetrahydrofuran is preferable.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 50 to 100°C. While the reaction time varies depending on the kind of compound (XXIX) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (XXXII) or a salt thereof by reacting compound (XXXI) or a salt thereof with compound (XVIII) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XXXI) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XXXIII) or a salt thereof by reacting compound (XXXII) or a salt thereof with compound (VIIa) or a salt thereof in the presence of a base.
  • This step can be performed in the same manner as in the method described in Step 3 of Method A.
  • This step is a step of converting compound (XXXIII) or a salt thereof to compound (XXXIV) or a salt thereof by hydrolysis.
  • This step can be performed in the same manner as in the method described in Step 6 of Method A.
  • This step is a step of producing compound (I'k) or a salt thereof by reacting compound (XXXIV) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (XXXVb) or a salt thereof by subjecting compound (XXXVa) or a salt thereof to a dehydration reaction.
  • Compound (XXXVa) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • Examples of the reactant used for this reaction include sulfuric acid, sulfonic acids (methanesulfonic acid, p-toluenesulfonic acid etc.), thionyl chloride, phosphoryl chloride, diphosphorus pentaoxide, phosgene, triphosgene, anhydrides (acetic anhydride, trifluoroacetic anhydride etc.) and the like. While the amount of the reactant to be used varies depending on the kind of the solvent and other reaction condition, it is generally about 1 to 100 mol equivalent, preferably about 1 to 10 mol equivalent, per 1 mol of compound (XXXVa).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform, carbon tetrachloride etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the reactant may be used as
  • the reaction temperature is, for example, within about 0 to 200°C, preferably about 50 to 100°C. While the reaction time varies depending on the kind of compound (XXXVa) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (XXXVIII) or a salt thereof by reacting compound (XXXVa) or a salt thereof with compound (III) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (XXXVIII) or a salt thereof by reacting compound (XXXVb) or a salt thereof with compound (III) or a salt thereof.
  • This step can be performed in the same manner as in the method described in Step 1 of Method A.
  • This step is a step of producing compound (I'l) or a salt thereof by reacting compound (XXXVIII) or a salt thereof with compound (V) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • This step is a step of producing compound (I'm) or a salt thereof by treating compound (I'l) or a salt thereof with an oxidizing agent.
  • oxidizing agent used for this reaction examples include hydrogen peroxide, peracetic acid, periodates, metachloroperbenzoic acid, acyl nitrates, dinitrogen tetraoxide, halogen, N-halogen compounds (N-bromosuccinimide, N-chlorosuccinimide etc.) and the like. While the amount of the oxidizing agent to be used varies depending on the kind of the solvent and other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 10 mol equivalent, per 1 mol of compound (I'l).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform, carbon tetrachloride etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.), water and the like.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the oxidizing agent may
  • the reaction temperature is, for example, within about - 78 to 200°C, preferably about 0 to 50°C. While the reaction time varies depending on the kind of compound (I'l) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 500 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (I'n) or a salt thereof by treating compound (I'l) or a salt thereof with an oxidizing agent.
  • oxidizing agent used for this reaction examples include hydrogen peroxide, peracetic acid, hydroperoxides, potassium peroxydisulfate, permanganates, sodium perborate, periodates, metachloroperbenzoic acid, osmium(VII) oxide, ruthenium(VII) oxide, nitric acid, chromic acid, sodium dichromate, halogens, sodium hypochlorite, iodobenzene dichloride, iodobenzene diacetate, ozone, singlet oxygen and the like. While the amount of the oxidizing agent to be used varies depending on the kind of the solvent and other reaction condition, it is generally about 1 to 10 mol equivalent, preferably about 1 to 10 mol equivalent, per 1 mol of compound (I'l).
  • This reaction is generally performed in a solvent that does not adversely influence the reaction.
  • the solvent that does not adversely influence the reaction include aromatic hydrocarbons (benzene, toluene, xylene etc.), aliphatic hydrocarbons (hexane, heptane etc.), halogenated hydrocarbons (dichloromethane, chloroform, carbon tetrachloride etc.), ethers (diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran, dioxane, dimethoxyethane etc.), nitriles (acetonitrile etc.), esters (ethyl acetate etc.), amides (N,N-dimethylformamide etc.), sulfoxides (dimethylsulfoxide etc.), water and the like.
  • These solvent may be used in a mixture of two or more kinds thereof in an appropriate ratio.
  • the oxidizing agent may
  • the reaction temperature is, for example, within about - 78 to 200°C, preferably about 0 to 50°C. While the reaction time varies depending on the kind of compound (I'l) or a salt thereof, the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 24 hr.
  • This step is a step of producing compound (XXXXII) or a salt thereof by reacting compound (XXXX) or a salt thereof with compound (XXXXI) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XXXX) and compound (XXXXI) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XXXXIII) or a salt thereof by subjecting compound (XXXXII) or a salt thereof to a deprotection reaction.
  • This step can be performed in the same manner as in the method described in Step 2 of Method D.
  • This step is a step of producing compound (I'o) or a salt thereof by reacting compound (XXXXIII) or a salt thereof with compound (XXXXIV) or a salt thereof in the presence of a condensing agent.
  • This step can be performed in the same manner as in the method described in Step 2 of Method A.
  • Compound (XXXXIV) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • DMB is a 2,4-dimethoxybenzyl group, and the other each symbols are as defined above.
  • This step is a step of producing compound (XXXXV) or a salt thereof by subjecting compound (V) or a salt thereof to a reductive alkylation reaction with 2,4-dimethoxybenzaldehyde.
  • the reductive alkylation reaction in this step can be performed according to a method known per se.
  • compound (XXXXV) or a salt thereof can be produced by reacting compound (V) or a salt thereof with 2,4-dimethoxybenzaldehyde in the presence of titanium(IV) isopropoxide, and subjecting the resulting imine to a reduction reaction with sodium borohydride.
  • the amount of the 2,4-dimethoxybenzaldehyde to be used is generally about 0.5 to 5 mol equivalent, preferably about 0.5 to 1 mol equivalent, per 1 mol of compound (V).
  • the amount of the titanium(IV) isopropoxide to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (V).
  • the solvent used for the reaction for producing imine is not particularly limited as long as the reaction proceeds.
  • examples thereof include hydrocarbons (heptane, hexane, toluene, xylene etc.), halogenated hydrocarbons (chloroform, dichloromethane, 1,2-dichloroethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), esters (ethyl acetate, t-butyl acetate etc.), nitriles (acetonitrile, butyronitrile etc.), amides (N,N-dimethylformamide, dimethylacetamide etc.), sulfoxides (dimethylsulfoxide etc.) and the like, and mixed solvents thereof.
  • the reaction temperature is generally about 0°C to about 200°C, preferably about 30°C to about 150°C, and the reaction time is generally about 0.5 hr to about 48 hr, preferably about 0.5 hr to about 24 hr.
  • the amount of the sodium borohydride used for the reduction of the imine to be used is generally about 1 to 10 mol equivalent, preferably about 1 to 3 mol equivalent, per 1 mol of compound (V).
  • the reduction of the imine is performed generally in a solvent inert to the reaction.
  • the solvent include aromatic hydrocarbons (toluene, xylene etc.), aliphatic hydrocarbons (heptane, hexane etc.), halogenated hydrocarbons (chloroform, dichloromethane etc.), ethers (diethyl ether, tetrahydrofuran, dioxane etc.), alcohols (methanol, ethanol, 2-propanol, butanol, benzyl alcohol etc.), nitriles (acetonitrile etc.), N,N-dimethylformamide, dimethylsulfoxide and the like. These solvent may be used in a mixture thereof in an appropriate ratio.
  • the reaction temperature is generally about -80°C to about 80°C, preferably about -40°C to about 40°C, and the reaction time is generally about 5 min to about 48 hr, preferably about 1 hr to about 24 hr.
  • This step is a step of producing compound (XXXXVI) or a salt thereof by reacting compound (XXXXV) or a salt thereof with compound (IIb) or a salt thereof.
  • This step can be performed in the same manner as in the method described in Step 1 of Method A.
  • Compound (IIb) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (XXXXVII) or a salt thereof by treating compound (XXXXVI) or a salt thereof with a reducing agent.
  • This step can be performed in the same manner as in the method described in Step 1 of Method B.
  • This step is a step of producing compound (XXXXIX) or a salt thereof by reacting compound (XXXXVII) or a salt thereof with compound (XXXXVIII) or a salt thereof in the presence of a base.
  • This step can be performed in the same manner as in the method described in Step 2 of Method H.
  • Compound (XXXXVIII) may be a commercially available product, or can also be produced according to a method known per se or a method analogous thereto.
  • This step is a step of producing compound (I'p) or a salt thereof by subjecting compound (XXXXIX) or a salt thereof to a deprotection reaction.
  • the deprotection reaction can be performed according to a known method (e.g., Wiley-Interscience, 1999, "Protective Groups in Organic Synthesis, 3rd Ed.” (Theodora W. Greene, Peter G. m. Wuts )).
  • the deprotection reaction can be performed using anisole in trifluoroacetic acid as a solvent.
  • the amount of the trifluoroacetic acid to be used is generally 1 to 100 mL per 1 g of compound (XXXXIX).
  • the amount of the anisole to be used is generally 1 to 10 mL per 1 g of compound (XXXXIX).
  • the reaction temperature is, for example, within about - 50 to 100°C, preferably about 0 to 30°C. While the reaction time varies depending on the kind of compound (XXXXIX), the reaction temperature and the like, it is, for example, about 0.5 to 100 hr, preferably about 0.5 to 48 hr.
  • the object product When the object product is obtained in a free form by the above-mentioned reaction, it may be converted to a salt by a conventional method. When it is obtained as a salt, it can also be converted to a free form or other salt by a conventional method.
  • the thus-obtained compound (I') can be isolated and purified from the reaction solution by a known means, for example, phase transfer, concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography and the like.
  • compound (I') contains an isomer such as a tautomer, an optical isomer, a stereoisomer, a regioisomer, a rotamer and the like, any isomer and a mixture thereof are also encompassed in the compound of the present invention. Furthermore, when compound (I') has an optical isomer, an optical isomer resolved from this compound is also encompassed in compound (I').
  • the compound (I') may be a crystal. Even if compound (I') is in a single crystal form or mixed crystal form, it can be provided as compound (I') of the present invention.
  • Compound (I') may be a pharmaceutically acceptable co-crystal or co-crystal salt.
  • the co-crystal or co-crystal salt means a crystalline substance consisting of two or more particular substances which are solids at room temperature, each having different physical properties (e.g., structure, melting point, heat of melting, hygroscopicity, solubility, stability etc.).
  • the co-crystal and co-crystal salt can be produced by co-crystallization known per se.
  • the compound (I') may be a solvate (e.g., a hydrate) or a non-solvate. Any of them can be provided as compound (I') of the present invention.
  • any of the above compounds may be labeled or substituted with an isotope (e.g., 2 H, 3 H, 11 C, 14 C, 18 F, 35 S, 125 I etc.) and the like, and provided as compound (I') of the present invention.
  • Compound (I') labeled or substituted with an isotope can be used, for example, as a tracer (PET tracer) used for positron emission tomography (PET), and is useful in the field such as medical diagnosis and the like.
  • Compound (I') may be used in the form of a prodrug, which means a compound which can be converted into compound (I') by reaction with an enzyme, gastric acid, or the like under physiological conditions in the living body.
  • a prodrug means a compound which can be converted into compound (I') by reaction with an enzyme, gastric acid, or the like under physiological conditions in the living body.
  • it means a compound which can be converted into compound (I') by enzymatic oxidation, reduction, hydrolysis or the like, or a compound which can be converted into compound (I') by hydrolysis with gastric acid or the like.
  • prodrug of compound (I') examples include a compound in which amino of compound (I') is acylated, alkylated, or phosphorylated (e.g., the amino of compound ((I') is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, tert-butylated etc.); a compound in which hydroxyl of compound (I') is acylated, alkylated, phosphorylated, or borated (e.g., hydroxyl of compound (I') is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethyl
  • the prodrug of compound (I') may be a compound that converts to compound (I') under physiological conditions as described in Development of Pharmaceutical Products, vol. 7, Molecule Design, 163-198, Hirokawa Shoten (1990 ).
  • compound (I') [hereinafter sometimes to be abbreviated as the compound of the present invention] shows superior ROR ⁇ t inhibitory activity, it is also useful as a safe medicament based on such action.
  • the medicament of the present invention containing the compound of the present invention can be used for a mammal (e.g., mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human etc.) as a prophylactic or therapeutic agent for ROR ⁇ t associated diseases, Th17 cell associated diseases and IL-17A or IL-17F associated diseases, more specifically, the diseases described in (1) - (4) below.
  • a mammal e.g., mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human etc.
  • the medicament of the present invention can be used as a prophylactic or therapeutic agent for preferably autoimmune disease, inflammatory disease, bone or articular disease or neoplastic disease, particularly preferably, rheumatoid arthritis, inflammatory bowel disease, psoriasis, ankylosing spondylitis, bronchial asthma, chronic obstructive pulmonary diseases, ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, cervical cancer, prostate cancer or uterine body cancer.
  • the above-mentioned “prophylaxis” of a disease means, for example, administration of a medicament containing the compound of the present invention to patients who are expected to have a high risk of the onset due to some factor relating to the disease but have not developed the disease or patients who have developed the disease but do not have a subjective symptom, or administration of a medicament containing the compound of the present invention to patients who are feared to show recurrence of the disease after treatment of the disease.
  • the medicament of the present invention shows superior pharmacokinetics (e.g., a half-life of the drug in plasma), low toxicity (e.g., HERG inhibition, CYP inhibition, CYP induction), and decreased drug interaction.
  • the compound of the present invention can be directly used as a medicament, or as the medicament of the present invention by producing a pharmaceutical composition by mixing with a pharmaceutically acceptable carrier by a means known per se and generally used in a production method of pharmaceutical preparations.
  • the medicament of the present invention can be orally or parenterally administered safely to mammals (e.g., humans, monkeys, cows, horses, pigs, mice, rats, hamsters, rabbits, cats, dogs, sheep and goats).
  • a medicament containing the compound of the present invention can be safely administered solely or by mixing with a pharmacologically acceptable carrier according to a method known per se (e.g., the method described in the Japanese Pharmacopoeia etc.) as the production method of a pharmaceutical preparation, and in the form of, for example, tablet (including sugar-coated tablet, film-coated tablet, sublingual tablet, orally disintegrating tablet, buccal and the like), pill, powder, granule, capsule (including soft capsule, microcapsule), troche, syrup, liquid, emulsion, suspension, release control preparation (e.g., immediate-release preparation, sustained-release preparation, sustained-release microcapsule), aerosol, film (e.g., orally disintegrating film, oral mucosa-adhesive film), injection (e.g., subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection), drip infusion, transdermal absorption type preparation, ointment, lotion, adhesive preparation, suppository (e.g
  • the content of the compound of the present invention in the medicament of the present invention is about 0.01 to 100% by weight of the entire medicament.
  • the dose varies depending on the subject of administration, administration route, disease and the like, for example, for oral administration to an adult inflammatory bowel disease (IBD) patient (body weight about 60kg), it is about 0.1 mg/kg body weight to 30 mg/kg body weight, preferably about 1 mg/kg body weight to 20 mg/kg body weight as an active ingredient (compound (I')) for one day, which is administered once to several times (e.g., once to 3 times).
  • the pharmaceutically acceptable carrier which may be used for the production of the medicament of the present invention, may be exemplified by various organic or inorganic carrier materials that are conventionally used as preparation materials, for example, excipient, lubricant, bin ding agent and disintegrant for solid preparations; or solvent, solubilizing agent, suspending agent, isotonic agent, buffering agent, soothing agent and the like for liquid preparations.
  • solvent solubilizing agent, suspending agent, isotonic agent, buffering agent, soothing agent and the like for liquid preparations.
  • ordinary additives such as preservative, antioxidant, colorant, sweetening agent, adsorbing agent, wetting agent and the like can be also used as appropriate in an appropriate amount.
  • excipient examples include lactose, white sugar, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid and the like.
  • Examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
  • Examples of the binding agent include crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, carboxymethylcellulose sodium and the like.
  • disintegrant examples include starch, carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethylstarch sodium, L-hydroxypropylcellulose and the like.
  • solvent examples include water for injection, alcohol, propylene glycol, Macrogol, sesame oil, corn oil, olive oil and the like.
  • solubilizing agent examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
  • suspending agent examples include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; and the like.
  • surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate and the like
  • hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxy
  • isotonic agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
  • buffering agent examples include buffer solutions such as phosphates, acetates, carbonates, citrates and the like.
  • Examples of the soothing agent include benzyl alcohol and the like.
  • preservative examples include parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • antioxidant examples include sulfites, ascorbic acid, ⁇ -tocopherol and the like.
  • the compound of the present invention can also be used together with other medicaments.
  • a medicament to be used when the compound of the present invention is used together with other drug is referred to as "the combination agent of the present invention”.
  • the compound of the present invention when used as an ROR ⁇ t inhibitor, Th17 cell inhibitor, IL-17A or IL-17F inhibitor, it can be used in combination with the following drugs.
  • concomitant drugs include, for example, antibacterial agent, antifungal agent, antiprotozoal agent, antibiotic, antitussive and expectorant drug, sedative, anesthetic, antiulcer drug, antiarrhythmic agent, hypotensive diuretic drug, anticoagulant, tranquilizer, antipsychotic, antitumor drug, hypolipidemic drug, muscle relaxant, antiepileptic drug, antidepressant, antiallergic drug, cardiac stimulants, therapeutic drug for arrhythmia, vasodilator, vasoconstrictor, hypotensive diuretic, therapeutic drug for diabetes, antinarcotic, vitamin, vitamin derivative, antiasthmatic, therapeutic agent for pollakisuria/anischuria, therapeutic agent for atopic dermatitis, therapeutic agent for allergic rhinitis, hypertensor, endotoxin-antagonist or -antibody, signal transduction inhibitor, inhibitor of inflammatory mediator activity, antibody to inhibit inflammatory mediator activity, inhibitor of anti-inflammatory
  • the administration time of the compound of the present invention and the concomitant drug is not restricted, and the compound of the present invention or the concomitant drug can be administered to an administration subject simultaneously, or may be administered at different times.
  • the dosage of the concomitant drug may be determined according to the dose clinically used, and can be appropriately selected depending on an administration subject, administration route, disease, combination and the like.
  • administration form of the combined use is not particularly limited, and the compound of the present invention and a concomitant drug only need to be combined on administration.
  • administration mode include the following:
  • the mixing ratio of the compound of the present invention and a concomitant drug in the combination agent of the present invention can be appropriately selected based on the subject of administration, administration route, disease and the like.
  • the content of the compound of the present invention in the combination agent of the present invention varies depending on the preparation form, it is generally about 0.01 - 100 wt%, preferably about 0.1 - 50 wt%, more preferably about 0.5 - 20 wt%, of the whole preparation.
  • the content of the concomitant drug in the combination agent of the present invention varies depending on the preparation form, and generally about 0.01 to 100% by weight, preferably about 0.1 to 50% by weight, further preferably about 0.5 to 20% by weight, of the entire preparation.
  • the content of the additive such as a carrier and the like in the combination agent of the present invention varies depending on the form of a preparation, it is generally about 1 to 99.99% by weight, preferably about 10 to 90% by weight, based on the preparation.
  • the dose of the combination agent varies depending on the kind of the compound of the present invention, administration route, symptom, age of patients and the like.
  • administration route for oral administration to patients (body weight about 60 kg) with inflammatory bowel disease (IBD), about 0.1 mg/kg body weight - about 30 mg/kg body weight, preferably about 1 mg/kg body weight - 20 mg/kg body weight, of compound (I) or (I') can be administered once to several portions (e.g., once to 3 times) per day.
  • the dose of the pharmaceutical composition of the present invention as a sustained-release preparation varies depending on the kind and content of compound (I'), dosage form, period of sustained drug release, subject animal of administration (e.g., mammals such as mouse, rat, hamster, guinea pig, rabbit, cat, dog, bovine, horse, swine, sheep, monkey, human and the like), and administration object.
  • subject animal of administration e.g., mammals such as mouse, rat, hamster, guinea pig, rabbit, cat, dog, bovine, horse, swine, sheep, monkey, human and the like
  • administration object e.g., mammals such as mouse, rat, hamster, guinea pig, rabbit, cat, dog, bovine, horse, swine, sheep, monkey, human and the like
  • administration object e.g., mammals such as mouse, rat, hamster, guinea pig, rabbit, cat, dog, bovine, horse, swine, sheep, monkey
  • the daily dosage in terms of the concomitant drug varies depending on the severity, age, sex, body weight, sensitivity difference of the subject, administration period, interval, and nature, pharmacology, kind of the pharmaceutical preparation, kind of effective ingredient, and the like, and not particularly restricted, and the amount of a drug is, in the case of oral administration for example, generally about 0.001 to 2000 mg, preferably about 0.01 to 500 mg, further preferably about 0.1 to 100 mg, per 1 kg of a mammal and this is generally administered once to 4-times (preferably, once to 3-times) divided in a day.
  • the compound of the present invention and the concomitant drug can be administered simultaneously, or may be administered in a staggered manner.
  • the interval varies depending on the effective ingredient, dosage form and administration method, and, for example, when the concomitant drug is administered first, a method in which the compound of the present invention is administered within time range of from 1 minute to 3 days, preferably from 10 minutes to 1 day, more preferably from 15 minutes to 1 hour, after administration of the concomitant drug is an example.
  • a method in which the concomitant drug is administered within time range of from 1 minute to 1 day, preferably from 10 minutes to 6 hours, more preferably from 15 minutes to 1 hour after administration of the compound of the present invention is an example.
  • the elution in column chromatography in the Examples was performed under observation by TLC (Thin Layer Chromatography).
  • TLC observation 60F254 manufactured by Merck was used as a TLC plate, and the solvent used as an elution solvent for column chromatography was used.
  • detection moreover, a UV detector was adopted.
  • silica gel for column chromatography silica gel 60 (70-230 mesh) manufactured by Merck was used.
  • the room temperature generally means a temperature about 10°C to 35°C.
  • sodium sulfate or magnesium sulfate was used.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 80% ethyl acetate/hexane) to give the title compound (82 mg, 0.193 mmol, 40.5%) as a pale-yellow powder.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 5 to 75% ethyl acetate/hexane), and then NH-silica gel column chromatography (solvent gradient; 5 to 100% ethyl acetate/hexane) to give the title compound (189 mg, 0.372 mmol, 39.0%) as a white powder.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 60% ethyl acetate/hexane), and crystallized from ethyl acetate and hexane to give tert-butyl (1-(((9-ethyl-9H-carbazol-3-yl)methyl)amino)-1-oxopropan-2-yl)carbamate (324 mg, 0.819 mmol, 78%) as a white powder.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 5 to 75% ethyl acetate/hexane) to give the title compound (458 mg, 0.996 mmol, 64.6%) as a colorless powder.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 50% ethyl acetate/hexane), and crystallized from ethyl acetate to give the title compound (0.187 g, 0.350 mmol, 9.98%) as white crystals.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 100% ethyl acetate/hexane), and crystallized from ethyl acetate and ethanol to give the title compound (82 mg, 0.174 mmol, 6.10%) as colorless crystals.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 85% ethyl acetate/hexane), and purified by NH-silica gel column chromatography (solvent gradient; 10 to 100% ethyl acetate/hexane) to give the title compound (0.788 g, 1.681 mmol, 38.7%) as a colorless powder.
  • the obtained residue was purified by silica gel column chromatography (solvent gradient; 10 to 100% ethyl acetate/hexane), and purified by preparative HPLC (column: L-Column 2 ODS, eluent: 0.1% TFA-containing acetonitrile/water) to give the compound of Example 42 (42.0 mg, 0.089 mmol, 3.32%) and the compound of Example 43 (20.00 mg, 0.042 mmol, 1.583%), each as a white powder.
  • Step 1 The compound obtained in Step 1 (21.69 g, 98.31 mmol), DBU (16.30 mL, 108.14 mmol) and nitromethane (6.00 g, 98.31 mmol) were stirred at room temperature for 14 hr. To the reaction solution was added brine at room temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and dried, and the solvent was evaporated under reduced pressure.
  • reaction solution was concentrated under reduced pressure, and the precipitate was triturated with 20% ethyl acetate/hexane to give a mixture (10.4 g, 98.6%) of N-(2,4-dimethoxybenzyl)-N-(9-ethyl-9H-carbazol-3-yl)-2-methylsuccinamidic acid and a regioisomer thereof, as a white powder.
  • the regioisomeric mixture was used for the next step without purification.
  • the obtained residue was purified by silica gel column chromatography (solvent; 4% methanol/dichloromethane) to give a mixture (6 g, 59.4%) of N-(2,4-dimethoxybenzyl)-N-(9-ethyl-9H-carbazol-3-yl)-4-hydroxy-3-methylbutylamide and a regioisomer thereof, as a white powder.
  • the regioisomeric mixture was used for the next step without further purification.
  • the obtained residue was purified by silica gel column chromatography (solvent; 30% ethyl acetate/hexane) to give a mixture (1 g, 40%) of 4-(4-cyanobenzyloxy)-N-(2,4-dimethoxybenzyl)-N-(9-ethyl-9H-carbazol-3-yl)-3-methylbutylamide and a regioisomer thereof, as a white powder.
  • the regioisomeric mixture was used for the next step without further purification.
  • Example No. 1 structural formula salt free
  • Example No. 2 structural formula salt free
  • Example No. 3 structural formula salt free
  • Example No. 4 structural formula salt free
  • Example No. 5 structural formula salt free
  • Example No. 6 structural formula salt free
  • Example No. 7 structural formula salt free
  • Example No. 8 structural formula salt free
  • Example No. 9 structural formula salt free
  • Example No. 10 structural formula salt free
  • Example No. 11 structural formula salt free
  • Example No. 13 structural formula salt free
  • Example No. 14 structural formula salt free
  • Example No. 15-step 1 structural formula salt free Table 1-2 Example No. 15 structural formula salt free
  • Example No. 16 structural formula salt free
  • Example No. 17 structural formula salt free
  • Example No. 17 structural formula salt free
  • the binding activity of the test compound to ROR ⁇ t was measured by a time resolved fluorescence resonance energy transfer method (TR-FRET) utilizing histidine-tagged RORyt, fluorescent-labeled cholesterol (BODIPY-cholesterol, AVIVA) and terbium-labeled anti-histidine tag antibody (Invitrogen).
  • TR-FRET time resolved fluorescence resonance energy transfer method
  • Table 2 Test compound (Example No.) binding inhibitory rate (%) 3 88.2 4 99.4 14 101.0 16 97.8 18 87.2 19 98.9 20 98.7 24 98.9 25 101.0 26 99.7 30 94.4 34 94.6 38 91.9 39 91.4 40 96.3 41 93.4 42 101.0 43 100.0 44 62.9 48 104.0 49 93.9 50 88.8 55 82.2
  • Cofactor recruitment test was performed by Alpha Screen (Histidine Detection Kit, PerkinElmer) method. First, a test compound diluted with an assay buffer (50 mM Tris-HCl (pH 7.5), 50 mM KCl, 1 mM DTT, 0.1% BSA) was added to a 384 well plate by 5 ⁇ L each.
  • an assay buffer 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 1 mM DTT, 0.1% BSA
  • ROR ⁇ t diluted with an assay buffer to 125 nM was added by 10 ⁇ L each, after which solutions of 25 nM biotinylated SRC-1 peptide (biotin-CLTARHKILHRLLQEGSPSD), 12.5 ⁇ g/mL acceptor beads and 12.5 ⁇ g/mL donor beads, which was prepared with the assay buffer, were added by 10 ⁇ L each.
  • the mixture was stood in a dark place for 1 hr, and the signal value was measured by Envision (PerkinElmer).
  • the Jurkat cells used for the reporter test were cultured in a culture medium (RPMI (Invitrogen), 10% FCS (AusGeneX), 100 U/mL penicillin, 100 ⁇ g/mL streptomycin).
  • RPMI Invitrogen
  • FCS AusGeneX
  • 100 U/mL penicillin 100 ⁇ g/mL streptomycin.
  • 4 ⁇ 10 7 cells were recovered by a centrifugal operation (1000 rpm, 5 min.) and suspended in PBS (phosphate buffered saline) (Invitrogen). Thereafter, the cells were recovered again by a centrifugal operation, and suspended in 2 mL of R buffer (NEON transfection kit, Invitrogen).
  • a reporter vector 53 ⁇ g wherein a human IL-17 ROR response element was inserted into the upstream of luciferase of pGL 4.28 (Promega), and a vector (27 ⁇ g) wherein ROR ⁇ t sequence was inserted into the downstream of CMV promoter were added to the cell suspension.
  • Gene transfer was performed by Electroporation apparatus (NEON, Invitrogen) under the conditions of pulse voltage 1350 V, interval 10 milliseconds, number of times 3.
  • the cells after gene transfer were suspended in 40 mL of a reaction medium (RPMI, 10% Lipid reduced FCS (HyClone), 10 mM HEPES (pH 7.5), 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 5 ⁇ M lovastatin), and plated in a 96 well plate by 90 ⁇ L each.
  • a test compound diluted with the reaction medium was added by 10 ⁇ L each, and the cells were cultured overnight in an incubator.
  • Bright-Glo Promega
  • CD4 positive naive T cells were collected from the spleen cells of BALB/c mice (female, 8-11w, Charles River Laboratories Japan, Inc.) using CD4+CD62L+ T Cell Isolation kit II (Miltenyi Biotec).
  • the CD4 positive naive T cells in a 96 well plate (3 ⁇ 10 5 cells/well) were stimulated (37°C for culture) with anti-mouse CD3 ⁇ antibody (Bio X cell) (10 ⁇ g/mL, solid phase) and anti-CD28 antibody (Bio X cell) (5 ⁇ g/mL) for 4 days in the presence of anti-IFN- ⁇ antibody (BioLegend), anti-IL-4 antibody (BioLegend), anti-IL-2 antibody (BioLegend), IL-6, TGF- ⁇ and IL-23 to differentiate into Th17 cells.
  • the compound was dissolved in DMSO and then added thereto.
  • the cells were cultured under these conditions for 4 days, and differentiation of the Th17 cells was evaluated by using the concentration of IL-17A, which was measured by ELISA, in the culture supernatant obtained by centrifugation.
  • CD4 positive naive T cells were isolated from peripheral blood mononuclear cells (PBMC) collected from human peripheral blood by a density gradient centrifugation method.
  • the CD4 positive naive T cells were seeded in a 96 well plate (2 ⁇ 10 4 cells/well), and stimulated (37°C for culture) with anti-CD3/28Ab Dynabeads (Invitrogen) for 6 days in the presence of IL-1 ⁇ , IL-6, IL-23, TGF ⁇ , anti-IFN ⁇ Ab (BioLegend) and anti-IL-4 Ab (BioLegend) to differentiate into Th17 cells.
  • the compound was dissolved in DMSO and then added thereto. After culture for 6 days, the concentration of IL-17A in the culture supernatant obtained by centrifugation was measured by ELISA to evaluate differentiation of the Th17 cells.
  • PBMC Peripheral blood mononuclear cells collected from human peripheral blood by a density gradient centrifugation method were stimulated by Dynabeads (registered trade mark; anti-CD3/CD28 antibody) and cultured at 37°C for 3 days. The compound was dissolved in DMSO and then added thereto. After culture for 3 days under such conditions, the concentration of IL-17A in the culture supernatant obtained by centrifugation was measured by ELISA to evaluate the effect of the compound on IL-17 production.
  • Dynabeads registered trade mark; anti-CD3/CD28 antibody
  • mice Female, 8 weeks old.
  • mice were anesthetized by ether inhalation, and euthanized by cervical spine fracture dislocation. Then, the mice underwent laparotomy, and colons were isolated. The obtained colons were washed with saline, and then, immersed in RNA stabilization buffer (RNAlater, QIAGEN) at 4°C for 18 hours or longer. Meanwhile, a suspension of a compound in 0.5% methylcellulose was orally administered an hour before administration of anti-CD3 antibody.
  • RNA stabilization buffer RNAlater, QIAGEN
  • TaqMan universal master mixII (Applied biosystems) was used as PCR buffer, and TaqMan Gene Expression Assays (Applied biosystems): Mm00439619_m1 (IL-17A), Mm00801778 m1 (IFN- ⁇ ) and 43252341E ( ⁇ -actin) were used for detection of each cytokine gene, respectively. The expression levels of each gene were shown as normalized values calculated using ⁇ -actin expression level.
  • a killed Mycobacterium tuberculosis, H37Ra (DIFCO) was suspended at the concentration of 2 mg/mL in Freund Incomplete adjuvant (DIFCO), and 5 mg of MBP (Sigma) was dissolved in 1.25 mL of saline (Otsuka). These two solutions were mixed at the ratio of 1:1 using glass syringe with a three-way stopcock until emulsion was obtained. The emulsion was intracutaneously administered to the bottom of the right foot of Lewis rats (male, 7 weeks old) at 0.1 mL/rat.
  • a suspension of the compound of Example 14 in 0.5% methylcellulose was orally administered twice a day from the day of sensitization at the dose of 30, 100 or 300 mg/kg. The last administration was performed on the 5 th day after sensitization, and an autopsy was performed 4 hours after the last administration.
  • the autopsy was performed on the 5 th day after the sensitization, and popliteal lymph nodes of the right leg were collected.
  • the lymph nodes were immersed in RNA later (Applied Biosystems), stored at 4°C overnight, and then, the lymph nodes were homogenized with a homogenizer in 1 mL of Isogen (Wako), and total RNA was purified.
  • cDNA was synthesized by reverse transcription reaction using High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems).
  • the synthesized cDNA was detected by PCR reaction using TaqMan Gene Expression Master Mix (Applied Biosystems) and 7900HT Fast realtime PCR system (Applied Biosystems)(Stage 1: 50°C, 2 min, Stage 2: 95°C, 10 min, Stage 3: 95°C, 15 sec, 60°C, 1 min, 40 cycle).
  • the primers and probes used in the reaction are as follows.
  • Example 14 (30, 100 and 300 mg/kg, po) tended to suppress the increase in IL-17A gene expression in lymph node of EAE-sensitized rat in a dose-dependent manner ( Fig.3 ).
  • the compound of the present invention has a superior ROR ⁇ t inhibitory action, and is useful as an agent for the prophylaxis or treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, and/or psoriasis.
  • IBD inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn's disease
  • rheumatoid arthritis multiple sclerosis
  • psoriasis psoriasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Claims (11)

  1. Verbindung, die durch die Formel (I') wiedergegeben ist:
    Figure imgb0166
     wobei
    R1A eine C1-6-Alkylgruppe ist,
    R2A und R3A jeweils unabhängig ein Wasserstoffatom oder eine C1-6-Alkylgruppe sind oder R2A und R3A zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, einen Arenring oder einen Cycloalkenring bilden,
    R5A ein Wasserstoffatom oder ein Halogenatom ist,
    Q' eine bivalente Gruppe ist, ausgewählt aus
    (1) einer Gruppe, die durch die Formel (I'a) wiedergegeben ist:
    Figure imgb0167
     wobei n eine ganze Zahl von 2 bis 4 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Phenylgruppe(n) oder C1-6-Alkylgruppe(n), ist, wobei die zwei an das einzelne Kohlenstoffatom gebundenen Substituenten optional miteinander kombiniert sind, um einen Cycloalkanring zu bilden, oder die Methylengruppe optional mit dem Substituenten an der benachbarten Methylengruppe kombiniert ist, um einen Cycloalkanring zu bilden;
    (2) einer Gruppe, die durch die Formel (I'b) wiedergegeben ist:
    Figure imgb0168
     wobei n = 3 ist, [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist und R4A und R4B gleich oder verschieden sind und jedes eine C1-6-Alkylgruppe ist;
    (3) einer Gruppe, die durch die Formel (I'c) wiedergegeben ist:
    Figure imgb0169
     wobei n = 3 ist, [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist und R4A eine C1-6-Alkylgruppe, optional substituiert durch C1-6-Alkoxygruppe(n), oder eine C7-12-Aralkylgruppe ist;
    (4) einer Gruppe, die durch die Formel (I'd) wiedergegeben ist:
    Figure imgb0170
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (5) einer Gruppe, die durch die Formel (I'e) wiedergegeben ist:
    Figure imgb0171
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (6) einer Gruppe, die durch die Formel (I'f) wiedergegeben ist:
    Figure imgb0172
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (7) einer Gruppe, die durch die Formel (I'g) wiedergegeben ist:
    Figure imgb0173
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (8) einer Gruppe, die durch die Formel (I'h) wiedergegeben ist:
    Figure imgb0174
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (9) einer Gruppe, die durch die Formel (I'i) wiedergegeben ist:
    Figure imgb0175
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (10) einer Gruppe, die durch die Formel (I'j) wiedergegeben ist:
    Figure imgb0176
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Hydroxygruppe(n) oder C1-6-Alkylgruppe(n), ist;
    (11) einer Gruppe, die durch die Formel (I'k) wiedergegeben ist:
    Figure imgb0177
     wobei n = 3 ist, [A1] Methylengruppen sind und R4A eine C1-6-Alkylgruppe, optional substituiert durch C1-6-Alkoxygruppe(n), ist;
    (12) einer Gruppe, die durch die Formel (I'l) wiedergegeben ist:
    Figure imgb0178
     wobei X' ein Schwefelatom oder eine Iminogruppe mit einer C1-6-Alkylgruppe ist, [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (13) einer Gruppe, die durch die Formel (I'm) wiedergegeben ist:
    Figure imgb0179
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (14) einer Gruppe, die durch die Formel (I'n) wiedergegeben ist:
    Figure imgb0180
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (15) einer Gruppe, die durch die Formel (I'o) wiedergegeben ist:
    Figure imgb0181
     wobei n" = 1 ist und [A1] eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist; und
    (16) einer Gruppe, die durch die Formel (I'p) wiedergegeben ist:
    Figure imgb0182
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist und
    Ring B'
    (1) ein Benzolring, optional mit zusätzlichem beziehungsweise zusätzlichen Substituenten, ausgewählt aus einem Halogenatom, einer Cyanogruppe, einer C1-6-Alkoxygruppe und einer C1-6-Alkylgruppe, optional substituiert durch 1 bis 3 Halogenatome, oder
    (2) ein Pyridinring, optional mit C1-6-Alkylgruppe(n),
    ist,
    vorausgesetzt, dass N-(4-Cyanophenyl)-N'-(9-ethyl-9H-carbazol-3-yl)-3-methylpentandiamid ausgeschlossen ist,
    oder ein Salz davon.
  2. Verbindung oder Salz nach Anspruch 1, wobei
    R5A ein Wasserstoffatom ist und
    Ring B' ein Benzolring, optional mit zusätzlichem beziehungsweise zusätzlichen Substituenten, ausgewählt aus einem Halogenatom, einer C1-6-Alkoxygruppe und einer C1-6-Alkylgruppe, optional substituiert durch 1 bis 3 Halogenatome, ist.
  3. Verbindung oder Salz nach Anspruch 1, wobei R2A und R3A jeweils unabhängig eine C1-6-Alkylgruppe sind oder R2A und R3A zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, einen Arenring oder einen Cycloalkenring bilden.
  4. Verbindung oder Salz nach Anspruch 1, wobei Q' eine bivalente Gruppe ist, ausgewählt aus
    (1) einer Gruppe, die durch die Formel (I'a) wiedergegeben ist:
    Figure imgb0183
     wobei n eine ganze Zahl von 2 bis 4 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Phenylgruppe(n) oder C1-6-Alkylgruppe(n), ist, wobei die zwei an das einzelne Kohlenstoffatom gebundenen Substituenten optional miteinander kombiniert sind, um einen Cycloalkanring zu bilden, oder die Methylengruppe optional mit dem Substituenten an der benachbarten Methylengruppe kombiniert ist, um einen Cycloalkanring zu bilden;
    (2) einer Gruppe, die durch die Formel (I'f) wiedergegeben ist:
    Figure imgb0184
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (3) einer Gruppe, die durch die Formel (I'j) wiedergegeben ist:
    Figure imgb0185
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Hydroxygruppe(n) oder C1-6-Alkylgruppe(n), ist;
    (4) einer Gruppe, die durch die Formel (I'l') wiedergegeben ist:
    Figure imgb0186
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind; und
    (5) einer Gruppe, die durch die Formel (I'n) wiedergegeben ist:
    Figure imgb0187
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind.
  5. Verbindung oder Salz nach Anspruch 1, die N-(4-Cyanophenyl)-N'-(9-ethyl-2,3,4,9-tetrahydro-1H-carbazol-6-yl)-3-methylpentandiamid oder ein Salz davon ist.
  6. Verbindung oder Salz nach Anspruch 1, die N-(3-Chlor-4-cyanophenyl)-N'-(9-ethyl-9H-carbazol-3-yl)-3-methylpentandiamid oder ein Salz davon ist.
  7. Verbindung oder Salz nach Anspruch 1, die N-{4-[(3-Chlor-4-cyanophenyl)amino]-2-methyl-4-oxobutyl}-9-ethyl-9H-carbazol-3-carboxamid oder ein Salz davon ist.
  8. Medikament zur Verwendung bei der Prophylaxe oder Behandlung von Autoimmunerkrankung, entzündlicher Erkrankung, Knochen- oder artikulärer Erkrankung oder neoplastischer Erkrankung, das eine Verbindung umfasst, die durch die Formel (I') wiedergegeben ist:
    Figure imgb0188
     wobei
    R1A eine C1-6-Alkylgruppe ist,
    R2A und R3A jeweils unabhängig ein Wasserstoffatom oder eine C1-6-Alkylgruppe sind oder R2A und R3A zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, einen Arenring oder einen Cycloalkenring bilden,
    R5A ein Wasserstoffatom oder ein Halogenatom ist,
    Q' eine bivalente Gruppe ist, ausgewählt aus
    (1) einer Gruppe, die durch die Formel (I'a) wiedergegeben ist:
    Figure imgb0189
     wobei n eine ganze Zahl von 2 bis 4 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Phenylgruppe(n) oder C1-6-Alkylgruppe(n), ist, wobei die zwei an das einzelne Kohlenstoffatom gebundenen Substituenten optional miteinander kombiniert sind, um einen Cycloalkanring zu bilden, oder die Methylengruppe optional mit dem Substituenten an der benachbarten Methylengruppe kombiniert ist, um einen Cycloalkanring zu bilden;
    (2) einer Gruppe, die durch die Formel (I'b) wiedergegeben ist:
    Figure imgb0190
     wobei n = 3 ist, [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist und R4A und R4B gleich oder verschieden sind und jedes eine C1-6-Alkylgruppe ist;
    (3) einer Gruppe, die durch die Formel (I'c) wiedergegeben ist:
    Figure imgb0191
     wobei n = 3 ist, [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), sind und R4A eine C1-6-Alkylgruppe, optional substituiert durch C1-6-Alkoxygruppe(n), oder eine C7-12-Aralkylgruppe ist;
    (4) einer Gruppe, die durch die Formel (I'd) wiedergegeben ist:
    Figure imgb0192
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (5) einer Gruppe, die durch die Formel (I'e) wiedergegeben ist:
    Figure imgb0193
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (6) einer Gruppe, die durch die Formel (I'f) wiedergegeben ist:
    Figure imgb0194
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (7) einer Gruppe, die durch die Formel (I'g) wiedergegeben ist:
    Figure imgb0195
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (8) einer Gruppe, die durch die Formel (I'h) wiedergegeben ist:
    Figure imgb0196
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (9) einer Gruppe, die durch die Formel (I'i) wiedergegeben ist:
    Figure imgb0197
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist;
    (10) einer Gruppe, die durch die Formel (I'j) wiedergegeben ist:
    Figure imgb0198
     wobei n = 3 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch Hydroxygruppe(n) oder C1-6-Alkylgruppe(n), ist;
    (11) einer Gruppe, die durch die Formel (I'k) wiedergegeben ist:
    Figure imgb0199
     wobei n = 3 ist, [A1] Methylengruppen sind und R4A eine C1-6-Alkylgruppe, optional substituiert durch C1-6-Alkoxygruppe(n), ist;
    (12) einer Gruppe, die durch die Formel (I'l) wiedergegeben ist:
    Figure imgb0200
     wobei X' ein Schwefelatom oder eine Iminogruppe mit einer C1-6-Alkylgruppe ist, [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (13) einer Gruppe, die durch die Formel (I'm) wiedergegeben ist:
    Figure imgb0201
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (14) einer Gruppe, die durch die Formel (I'n) wiedergegeben ist:
    Figure imgb0202
     wobei [A1] und [A2] Methylengruppen sind und x' und y' jeweils 1 sind;
    (15) einer Gruppe, die durch die Formel (I'o) wiedergegeben ist:
    Figure imgb0203
     wobei n" = 1 ist und [A1] eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist; und
    (16) einer Gruppe, die durch die Formel (I'p) wiedergegeben ist:
    Figure imgb0204
     wobei n' = 2 ist und [A1] gleich oder verschieden sind und jedes eine Methylengruppe, optional substituiert durch C1-6-Alkylgruppe(n), ist und
    Ring B'
    (1) ein Benzolring, optional mit zusätzlichem beziehungsweise zusätzlichen Substituenten, ausgewählt aus einem Halogenatom, einer Cyanogruppe, einer C1-6-Alkoxygruppe und einer C1-6-Alkylgruppe, optional substituiert durch 1 bis 3 Halogenatome, oder
    (2) ein Pyridinring, optional mit C1-6-Alkylgruppe(n),
    ist,
    oder ein pharmazeutisch akzeptables Salz davon.
  9. Medikament zur Verwendung gemäß Anspruch 8, wobei die Störung entzündliche Darmerkrankung (IBD), ulzeröse Kolitis (UC), Crohn-Krankheit (CD), rheumatoide Arthritis, multiple Sklerose oder Psoriasis ist.
  10. Verbindung oder pharmazeutisch akzeptables Salz nach Anspruch 1 zur Verwendung bei der Prophylaxe oder Behandlung von Autoimmunerkrankung, entzündlicher Erkrankung, Knochen- oder artikulärer Erkrankung oder neoplastischer Erkrankung.
  11. Verbindung oder pharmazeutisch akzeptables Salz zur Verwendung gemäß Anspruch 10, wobei die Störung entzündliche Darmerkrankung (IBD), ulzeröse Kolitis (UC), Crohn-Krankheit (CD), rheumatoide Arthritis, multiple Sklerose oder Psoriasis ist.
EP12833546.0A 2011-09-22 2012-09-21 Kondensierte heterocyclische verbindung Not-in-force EP2759533B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011207358 2011-09-22
PCT/JP2012/074282 WO2013042782A1 (ja) 2011-09-22 2012-09-21 縮合複素環化合物

Publications (3)

Publication Number Publication Date
EP2759533A1 EP2759533A1 (de) 2014-07-30
EP2759533A4 EP2759533A4 (de) 2015-04-01
EP2759533B1 true EP2759533B1 (de) 2017-08-02

Family

ID=47914540

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12833546.0A Not-in-force EP2759533B1 (de) 2011-09-22 2012-09-21 Kondensierte heterocyclische verbindung

Country Status (4)

Country Link
US (1) US9120776B2 (de)
EP (1) EP2759533B1 (de)
JP (1) JP6043290B2 (de)
WO (1) WO2013042782A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312901B (zh) * 2018-05-10 2024-05-14 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) * 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015031914A1 (en) * 2013-08-30 2015-03-05 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same
PL3102576T3 (pl) 2014-02-03 2019-12-31 Vitae Pharmaceuticals, Llc Dihydropirolopirydynowe inhibitory ror-gamma
WO2016002968A1 (en) * 2014-07-01 2016-01-07 Takeda Pharmaceutical Company Limited Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
CA2961033A1 (en) 2014-09-11 2016-03-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
UA118989C2 (uk) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Дигідропіролопіридинові інгібітори ror-гамма
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
KR102004721B1 (ko) * 2015-01-28 2019-07-29 베이징 한미 파마슈티컬 컴퍼니 리미티드 N-벤조산기로 치환된 벤조피롤린-2-온 유도체 및 이의 용도
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
KR102416718B1 (ko) 2016-08-31 2022-07-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 옥소피콜린아미드 유도체, 이에 대한 제조 방법 및 이의 약학적 용도
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
JP2022554390A (ja) 2019-11-05 2022-12-28 デルミラ インコーポレイテッド Ｒｏｒガンマｔ阻害剤およびその局所使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006717A1 (en) 1985-05-14 1986-11-20 William John Louis 3-aminopropyloxyphenyl derivatives their preparation and pharmaceutical compositions containing them
DK0906094T3 (da) 1996-01-02 2003-10-20 Aventis Pharma Inc Substituerede N-[(aminoiminomethyl- eller aminomethyl)phenyl]propylamider
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
ID22781A (id) * 1997-04-04 1999-12-09 Pfizer Prod Inc Turunan-turunan nikotinamida
EP1080075B1 (de) 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperidinyl- und n-amidinopiperidinyl-derivate
US20020016339A1 (en) 1998-03-23 2002-02-07 Klein Scott I. Piperididinyl and N-amidinopiperidinyl derivatives
SI1268418T1 (sl) * 2000-03-27 2006-10-31 Applied Research Systems Farmacevtsko aktivni pirolidinski derivati kot bax-inhibitorji
UA74362C2 (uk) 2000-03-27 2005-12-15 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Фармацевтично активні похідні піролідину
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
US7629471B2 (en) 2003-02-24 2009-12-08 Nrl Pharma, Inc. Transcriptional factor, process for producing the same and use thereof
WO2004098498A2 (en) 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
CA2573378A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
EP1855670A4 (de) 2005-02-24 2010-05-05 Merck Sharp & Dohme Benzazolverstärker von metabotropen-glutamatrezeptoren
JP5650540B2 (ja) * 2007-12-12 2015-01-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
EP2181710A1 (de) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Liganden zur Modulation der Orphan-Rezeptor-Gamma (NR1F3) Aktivität
WO2010065717A1 (en) 2008-12-05 2010-06-10 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
EP2404902A1 (de) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidin- und pyrrolidinderivate mit npy-y5-rezeptorantagonismus
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US9101600B2 (en) * 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US9150555B2 (en) 2010-10-14 2015-10-06 Mitsubishi Tanabe Pharma Corporation Amide derivative and use thereof
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
JP6054869B2 (ja) * 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
WO2013100027A1 (ja) * 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312901B (zh) * 2018-05-10 2024-05-14 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法

Also Published As

Publication number Publication date
JPWO2013042782A1 (ja) 2015-03-26
WO2013042782A1 (ja) 2013-03-28
JP6043290B2 (ja) 2016-12-14
US20140228409A1 (en) 2014-08-14
EP2759533A1 (de) 2014-07-30
US9120776B2 (en) 2015-09-01
EP2759533A4 (de) 2015-04-01

Similar Documents

Publication Publication Date Title
EP2759533B1 (de) Kondensierte heterocyclische verbindung
US11851449B2 (en) Heterocyclic amide compounds having an RORvt inhibitory action
EP2738170B1 (de) Heterocyclische verbindung
US9650343B2 (en) Heterocyclic compound
WO2013100027A1 (ja) 複素環化合物
EP1832588A1 (de) Kondensierte imidazolverbindung und deren verwendung
CN108368127A (zh) 1-取代的1,2,3,4-四氢-1,7-萘啶-8-胺衍生物及其作为ep4受体拮抗剂的用途
JP6280912B2 (ja) 複素環化合物
EP3018126A1 (de) Heterocyclische verbindung
EP3192791A1 (de) Heterocyclische verbindung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150302

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/08 20060101AFI20150224BHEP

Ipc: A61K 31/404 20060101ALI20150224BHEP

Ipc: A61P 43/00 20060101ALI20150224BHEP

Ipc: A61P 17/06 20060101ALI20150224BHEP

Ipc: A61P 19/02 20060101ALI20150224BHEP

Ipc: A61P 1/04 20060101ALI20150224BHEP

Ipc: A61P 29/00 20060101ALI20150224BHEP

Ipc: A61P 25/00 20060101ALI20150224BHEP

Ipc: A61K 31/403 20060101ALI20150224BHEP

Ipc: C07D 209/88 20060101ALI20150224BHEP

17Q First examination report despatched

Effective date: 20160113

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170224

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 914280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012035454

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170802

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 914280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170802

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171102

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171202

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171103

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171102

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012035454

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170921

26N No opposition filed

Effective date: 20180503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170921

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170921

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180911

Year of fee payment: 7

Ref country code: FR

Payment date: 20180813

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180919

Year of fee payment: 7

Ref country code: CH

Payment date: 20180913

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012035454

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200401

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170802

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190921